Compare NXL & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXL | TRIB |
|---|---|---|
| Founded | 2010 | 1992 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.4M |
| IPO Year | 2022 | 1996 |
| Metric | NXL | TRIB |
|---|---|---|
| Price | $4.82 | $7.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 116.6K | 26.9K |
| Earning Date | 05-11-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $301,647.00 | N/A |
| Revenue This Year | $15.52 | $13.51 |
| Revenue Next Year | $100.00 | $13.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 78.78 | N/A |
| 52 Week Low | $0.22 | $0.28 |
| 52 Week High | $7.69 | $14.17 |
| Indicator | NXL | TRIB |
|---|---|---|
| Relative Strength Index (RSI) | 70.21 | 38.37 |
| Support Level | $0.41 | $0.55 |
| Resistance Level | $7.69 | $14.03 |
| Average True Range (ATR) | 0.48 | 0.75 |
| MACD | 0.30 | -0.51 |
| Stochastic Oscillator | 65.06 | 12.67 |
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.